News 2020-03-16
Porton Announces Opening of US Technology Center.
Chongqing, China--Porton announced the establishment of Porton U.S.A, LLC, a new subsidiary and Process Innovation Center located in Cranbury, New Jersey (NJ), United States. Deploying state-of-the-art laboratories and some of the industry’s most capable and experienced scientists, Porton’s NJ Center will provide our customers with impactful solutions to complex process challenges, next generation process development, gram to kilogram cGMP syntheses of specialized pharmaceutical intermediates and APIs including highly potent APIs and antibody drug conjugates, etc. Through flexibly structured, yet close-knit collaborations and geographical proximity, Porton’s NJ Center will bring new efficiencies to pharmaceutical development and lifecycle management for our valued global customers.
Others
More
News 2025-07-31
Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology
Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes

News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.